Literature DB >> 33108472

Retinoblastoma cell-derived Twist protein promotes regulatory T cell development.

Ruishi Zhang1, Yan-Nan Song2, Xiaoyan Duo1, Zhihong Guo3, Yanhua Sun4, Zhixiong Zhang4, Yongtian Lu5, Beiping Miao6, Ping-Chang Yang7,8, Guohui Nie9.   

Abstract

BACKGROUND: The development of tumor tissue-infiltrating regulatory T cell (Treg) is incompletely understood. This study investigates the role of retinoblastoma cell (Rbc)-derived Twist‑related protein 1 (Twist) in the Treg development.
METHODS: The surgically removed Rb tissues were collected. Rbcs were cultured with CD4+ T cells to assess the role of Rbc-derived Twist in the Treg generation.
RESULTS: We found that more than 90% Rbcs expressed Twist. Foxp3+ Tregs were detected in the Rb tissues that were positively correlated with the Twist expression in Rbcs, negatively associated with Rb patient survival and sight survival. Treating Rbcs with hypoxia promoted the Twist expression that could be detected in the cytoplasm, nuclei and on the cell surface. Twist activated CD4+ T cells by binding the TLR4/myeloid differentiation factor 2 complex and promoted the transforming growth factor-β-inducible early gene 1 product and Foxp3 expression. These Rbc-induced Foxp3+ Tregs showed immune-suppressive function on CD8+ T cell proliferation.
CONCLUSIONS: Rbcs express Twist, that induces IL-4+ Foxp3+ Tregs; the latter can inhibit CD8+ cytotoxic T cell activities. Therefore, Twist may play an important role in the pathogenesis of Rb.

Entities:  

Keywords:  Apoptosis; Regulatory T cell; Retinoblastoma; Tumor tolerance; Twist

Year:  2020        PMID: 33108472     DOI: 10.1007/s00262-020-02744-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

Review 1.  The Biology of Retinoblastoma.

Authors:  Pia R Mendoza; Hans E Grossniklaus
Journal:  Prog Mol Biol Transl Sci       Date:  2015-07-14       Impact factor: 3.622

2.  Clinical Presentation and Outcomes of Stage III or Stage IV Retinoblastoma in 80 Asian Indian Patients.

Authors:  Swathi Kaliki; Anamika Patel; Sadiya Iram; Vijay Anand Reddy Palkonda
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2016-12-16       Impact factor: 1.402

Review 3.  Tolerance and exhaustion: defining mechanisms of T cell dysfunction.

Authors:  Andrea Schietinger; Philip D Greenberg
Journal:  Trends Immunol       Date:  2013-11-06       Impact factor: 16.687

Review 4.  Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Authors:  Yosuke Togashi; Kohei Shitara; Hiroyoshi Nishikawa
Journal:  Nat Rev Clin Oncol       Date:  2019-06       Impact factor: 66.675

Review 5.  Molecular targeted therapy of glioblastoma.

Authors:  Emilie Le Rhun; Matthias Preusser; Patrick Roth; David A Reardon; Martin van den Bent; Patrick Wen; Guido Reifenberger; Michael Weller
Journal:  Cancer Treat Rev       Date:  2019-09-11       Impact factor: 12.111

Review 6.  Retinoblastoma.

Authors:  Helen Dimaras; Timothy W Corson; David Cobrinik; Abby White; Junyang Zhao; Francis L Munier; David H Abramson; Carol L Shields; Guillermo L Chantada; Festus Njuguna; Brenda L Gallie
Journal:  Nat Rev Dis Primers       Date:  2015-08-27       Impact factor: 52.329

7.  Rb suppresses human cone-precursor-derived retinoblastoma tumours.

Authors:  Xiaoliang L Xu; Hardeep P Singh; Lu Wang; Dong-Lai Qi; Bradford K Poulos; David H Abramson; Suresh C Jhanwar; David Cobrinik
Journal:  Nature       Date:  2014-09-24       Impact factor: 49.962

Review 8.  Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.

Authors:  Pascale André; Caroline Denis; Caroline Soulas; Clarisse Bourbon-Caillet; Julie Lopez; Thomas Arnoux; Mathieu Bléry; Cécile Bonnafous; Laurent Gauthier; Ariane Morel; Benjamin Rossi; Romain Remark; Violette Breso; Elodie Bonnet; Guillaume Habif; Sophie Guia; Ana Ines Lalanne; Caroline Hoffmann; Olivier Lantz; Jérôme Fayette; Agnès Boyer-Chammard; Robert Zerbib; Pierre Dodion; Hormas Ghadially; Maria Jure-Kunkel; Yannis Morel; Ronald Herbst; Emilie Narni-Mancinelli; Roger B Cohen; Eric Vivier
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

Review 9.  A twist for survival and cancer progression.

Authors:  A Puisieux; S Valsesia-Wittmann; S Ansieau
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

10.  Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.

Authors:  Dalya R Soond; Roberto Pineiro; Khaled Ali; Thorsten Hagemann; Wayne Pearce; Ee Lyn Lim; Hicham Bouabe; Cheryl L Scudamore; Timothy Hancox; Heather Maecker; Lori Friedman; Martin Turner; Klaus Okkenhaug; Bart Vanhaesebroeck
Journal:  Nature       Date:  2014-06-11       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.